The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

ConclusionsThe model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels.Funding: CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research